TY - JOUR
T1 - Histone lysine demethylase 4B regulates general and unique gene expression signatures in hypoxic cancer cells
AU - Qiu, Lei
AU - Meng, Yang
AU - Wang, Lingli
AU - Gunewardena, Sumedha
AU - Liu, Sicheng
AU - Han, Junhong
AU - Krieg, Adam J.
N1 - Funding Information:
We thank the staff of the University of Kansas Medical Center Genomics Core for their core support services in the analyses and storage of the microarray data (Clark Bloomer). The research was supported by NIH grants: The Molecular Regulation of Cell Development and Differentiation‐COBRE (P30 GM122731‐03), Kansas Intellectual and Developmental Disabilities Research Center (NIH U54 HD 090216), the NIH S10 High‐End Instrumentation Grant (NIH S10OD021743), the Frontiers CTSA grant (UL1TR002366) at the University of Kansas Medical Center, as well as the National Natural Science Foundation of China (31972884, 81903083), the National Clinical Research Center for Geriatrics (Z20201007) and the 1·3·5 Project for Disciplines of Excellence, West China Hospital (ZYGD18003), Sichuan University.
Publisher Copyright:
© 2021 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.
PY - 2021/9
Y1 - 2021/9
N2 - The hypoxic tumor microenvironment promotes tumor survival by inducing the expression of genes involved in angiogenesis and metastasis. As a direct target of hypoxia-inducible factor, lysine demethylase 4B (KDM4B) is overexpressed in multiple cancers, suggesting that a general KDM4B regulatory mechanism may exist in these cancer types. In this study, we sought to further investigate the general and unique roles of KDM4B in ovarian, colon, and renal cancer cells. We first identified a set of potential KDM4B targets shared by SKOV3ip.1, HCT116, and RCC4 cell lines, as well as numerous genes specifically regulated in each cell line. Through Gene Ontology, KEGG, and Oncobox pathway analyses, we found that KDM4B primarily regulated biosynthetic and cell cycle pathways in normoxia, whereas in hypoxia, it regulated pathways associated with inflammatory response and migration. TCGA data analyses reveal high expression of KDM4B in multiple cancer types and differential expression across cancer stages. Kaplan–Meier plots suggest that elevated KDM4B expression may contribute to a better or worse prognosis in a manner specific to each cancer type. Overall, our findings suggest that KDM4B plays complex roles in regulating multiple cancer processes, providing a useful resource for the future development of cancer therapies that target KDM4B expression.
AB - The hypoxic tumor microenvironment promotes tumor survival by inducing the expression of genes involved in angiogenesis and metastasis. As a direct target of hypoxia-inducible factor, lysine demethylase 4B (KDM4B) is overexpressed in multiple cancers, suggesting that a general KDM4B regulatory mechanism may exist in these cancer types. In this study, we sought to further investigate the general and unique roles of KDM4B in ovarian, colon, and renal cancer cells. We first identified a set of potential KDM4B targets shared by SKOV3ip.1, HCT116, and RCC4 cell lines, as well as numerous genes specifically regulated in each cell line. Through Gene Ontology, KEGG, and Oncobox pathway analyses, we found that KDM4B primarily regulated biosynthetic and cell cycle pathways in normoxia, whereas in hypoxia, it regulated pathways associated with inflammatory response and migration. TCGA data analyses reveal high expression of KDM4B in multiple cancer types and differential expression across cancer stages. Kaplan–Meier plots suggest that elevated KDM4B expression may contribute to a better or worse prognosis in a manner specific to each cancer type. Overall, our findings suggest that KDM4B plays complex roles in regulating multiple cancer processes, providing a useful resource for the future development of cancer therapies that target KDM4B expression.
KW - colorectal cancer
KW - histone lysine demethylase 4B
KW - ovarian cancer
KW - renal cell carcinoma
KW - tumor hypoxia
UR - http://www.scopus.com/inward/record.url?scp=85129845059&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129845059&partnerID=8YFLogxK
U2 - 10.1002/mco2.85
DO - 10.1002/mco2.85
M3 - Article
AN - SCOPUS:85129845059
SN - 2688-2663
VL - 2
SP - 414
EP - 429
JO - MedComm
JF - MedComm
IS - 3
ER -